Literature DB >> 30222804

Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema.

Shaun I R Lampen, Rahul N Khurana, Glenn Noronha, David M Brown, Charles C Wykoff.   

Abstract

BACKGROUND AND
OBJECTIVE: To study anatomic changes in the suprachoroidal space (SCS) following suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension. PATIENTS AND METHODS: Eyes with diabetic macular edema receiving CLS-TA were imaged serially using anterior segment spectral-domain optical coherence tomography to examine the SCS.
RESULTS: At the final imaging session, the SCS was not significantly different in study eyes (n = 14; 8.4 μm) compared to fellow eyes (n = 10; 8.1 μm; P = .698). Two eyes were imaged immediately before and 30 minutes after suprachoroidal injections; in these eyes, mean suprachoroidal width increased significantly following CLS-TA injection, 9.9 μm to 75.1 μm (P < .001), and subsequently returned to 14.9 μm 1 month after the final injection (P = .221).
CONCLUSION: Suprachoroidal CLS-TA injection caused a measurable increase in the SCS, which returned to preinjection levels by 1 month following injection with no apparent lasting impact on SCS anatomy. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:692-697.]. Copyright 2018, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30222804     DOI: 10.3928/23258160-20180831-07

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  8 in total

1.  Triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema associated with uveitis.

Authors:  Joanne Thomas; Lucas Kim; Thomas Albini; Steven Yeh
Journal:  Expert Rev Ophthalmol       Date:  2022-08-21

2.  Collagenase injection into the suprachoroidal space of the eye to expand drug delivery coverage and increase posterior drug targeting.

Authors:  Jae Hwan Jung; Sanghyun Park; J Jeremy Chae; Mark R Prausnitz
Journal:  Exp Eye Res       Date:  2019-10-01       Impact factor: 3.467

3.  Noninvasive monitoring of suprachoroidal, subretinal, and intravitreal implants using confocal scanning laser ophthalmoscope (cSLO) and optical coherence tomography (OCT).

Authors:  Madhoosudan A Patil; Uday B Kompella
Journal:  Int J Pharm       Date:  2021-07-14       Impact factor: 6.510

4.  Safety and Efficacy of Suprachoroidal Injection of Triamcinolone in Treating Macular Edema Secondary to Noninfectious Uveitis.

Authors:  Junaid Hanif; Kashif Iqbal; Fauzia Perveen; Amina Arif; Rana N Iqbal; Farukh Jameel; Kashif Hanif; Ahmad Seemab; Ahmad Y Khan; Moiz Ahmed
Journal:  Cureus       Date:  2021-11-30

5.  Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes.

Authors:  Sook Hyun Chung; Iris Natalie Mollhoff; Alaknanda Mishra; Tzu-Ni Sin; Taylor Ngo; Thomas Ciulla; Paul Sieving; Sara M Thomasy; Glenn Yiu
Journal:  Hum Gene Ther       Date:  2021-04-08       Impact factor: 5.695

6.  Efficacy and safety of Suprachoroidal Triamcinolone Acetonide in cases of resistant diabetic Macular Edema.

Authors:  Haroon Tayyab; Chaudhry Nasir Ahmed; Muhammad Ali Ayaz Sadiq
Journal:  Pak J Med Sci       Date:  2020 Jan-Feb       Impact factor: 1.088

7.  Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders.

Authors:  Chen-Rei Wan; Barry Kapik; Charles C Wykoff; Christopher R Henry; Mark R Barakat; Milan Shah; Rafael V Andino; Thomas A Ciulla
Journal:  Transl Vis Sci Technol       Date:  2020-10-22       Impact factor: 3.283

Review 8.  Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases.

Authors:  Liron Naftali Ben Haim; Elad Moisseiev
Journal:  Pharmaceutics       Date:  2021-06-26       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.